Navigation Links
Fujirebio Diagnostics Named One of the Best Places to Work in Pennsylvania
Date:10/6/2008

Malvern-based company places as one of fifty best medium-sized companies

MALVERN, Pa., Oct. 6 /PRNewswire/ -- Fujirebio Diagnostics, Inc., a Malvern-based company, was recently named one of the Best Places to Work in PA for 2008 in a statewide survey and awards program created by a public/private partnership of Team Pennsylvania Foundation, the Pennsylvania Department of Community and Economic Development, the Pennsylvania Chamber of Business and Industry, and the Central Penn Business Journal. The Best Places to Work in PA program is designed to identify, recognize and honor the best places of employment in Pennsylvania, benefiting the state's economy, its workforce and businesses.

Fujirebio Diagnostics, the premier cancer diagnostics company and the industry leader in cancer biomarker assays, employs 125 people in Pennsylvania. Fujirebio Diagnostics specializes in the clinical development, manufacturing and commercialization of in-vitro diagnostic products for the management of human disease states, with an emphasis in oncology.

"Our strength is in our employees and we strive to create the best environment for them," said Paul Touhey, Chief Executive Officer and President, Fujirebio Diagnostics, Inc. "This commitment to our employees ultimately translates into quality service for our customers. We are extremely proud of our employees and this honor."

Created in 2000, the awards program is one of the first of its kind offered by a U.S. state. Fujirebio Diagnostics will be recognized and honored at the Best Places to Work in PA evening awards ceremony on Tuesday, December 2, 2008, at the Hershey Lodge & Convention Center. More information about the awards program can be found at http://www.bestplacestoworkinpa.com.

About FDI

Fujirebio Diagnostics, Inc. (FDI) is a premier diagnostics company and the industry leader in cancer biomarkers. FDI specializes in the clinical development, manufacturing and commercialization of in-vitro diagnostic products for the management of human disease states, with an emphasis in oncology. FDI utilizes its worldwide distribution network to enable access by physicians and patients to its diagnostic products. For more information about FDI, please call 610-240-3800 or visit http://www.fdi.com.


'/>"/>
SOURCE Fujirebio Diagnostics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Strategic Diagnostics to Present at Two Upcoming Investor Conferences
2. Strategic Diagnostics Updates Roth Conference Presentation Time
3. Alliance for Medical Devices, Instrumentation and Diagnostics formed between Fraunhofer Center for Manufacturing Innovation and Boston University
4. Rosetta Genomics to Present at the American Association of Cancer Research (AACR) "Molecular Diagnostics in Cancer Therapeutic Development" Conference
5. Indivumed Supports Roche Diagnostics With Immunohistochemistry Services and Clinical Specimens for Biomarker Discovery and Drug Development
6. Quest Diagnostics to Speak at the 2007 UBS Global Life Sciences Conference
7. BoVir(R) Named Best New Veterinary Diagnostics Product in International Animal Pharm Awards
8. Enigma Diagnostics Announces a European Commission Award of EUR3 Million to Fund the Development of a Point of Care Platform for the Rapid Diagnosis of Influenza Infections
9. MedAssets Supply Chain Systems Selects Siemens Medical Solutions Diagnostics for Chemistry, Automation and Immunoassay Solutions
10. Quest Diagnostics Joins National ePrescribing Patient Safety Initiative (NEPSI)
11. Roche Diagnostics Launches CoaguChek XS Plus System to Provide New PT/INR Point-of-Care Solution for Non-Waived Anticoagulation Services
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Brooklyn, NY (PRWEB) , ... June 24, 2016 , ... ... 15mm, machines such as the Cary 5000 and the 6000i models are higher end ... height is the height of the spectrophotometer’s light beam from the bottom of the ...
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
(Date:6/23/2016)... 2016  The Biodesign Challenge (BDC), a university competition ... harness living systems and biotechnology, announced its winning teams ... New York City . The ... projects at MoMA,s Celeste Bartos Theater during the daylong ... senior curator of architecture and design, and Suzanne ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
Breaking Biology Technology:
(Date:3/31/2016)... , March 31, 2016   ... ("LegacyXChange" or the "Company") LegacyXChange is excited ... of its soon to be launched online site for ... https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also provide potential shareholders a ... DNA technology to an industry that is notorious for ...
(Date:3/29/2016)... 29, 2016 LegacyXChange, Inc. (OTC: ... and SelectaDNA/CSI Protect are pleased to announce our successful ... a variety of writing instruments, ensuring athletes signatures against ... collectibles from athletes on LegacyXChange will be assured of ... DNA. Bill Bollander , CEO states, ...
(Date:3/22/2016)... India , March 22, 2016 /PRNewswire/ ... market research report "Electronic Sensors Market for Consumer ... Proximity, & Others), Application (Communication & IT, ... Geography - Global Forecast to 2022", published ... industry is expected to reach USD 26.76 ...
Breaking Biology News(10 mins):